Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 2Completed 2Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Hodgkin Disease 20Lymphoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphomatoid Papulosis 3Lymphoma, Large-Cell, Anaplastic 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Brentuximab Vedotin × 1 year × Clear all
NCT07624838 2026-06-03

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Recruiting
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Seagen Inc.

Phase 2 Completed
82 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07258680 2025-12-02

BrEto-TCL

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Enrolling by invitation
114 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

New York Medical College

Phase EARLY_PHASE1 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

The Lymphoma Academic Research Organisation

Phase 2 Completed
71 enrolled
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡